Mary Caffrey

Results from a registry study of patients from Australia and New Zealand show that 9.1% of patients with a new diagnosis of multiple myeloma die within a year of diagnosis, and infection contributed to early death in 38% of cases in which a cause of death was reported.

This the third installment of a series of interviews on Takeda’s partnership with Xavier University of Louisiana (T-REX), Takeda's Lauren Powell, MPA, PhD, discussed the impact Louisiana's hospital system has had on her work and the need for the pharmaceutical industry to invest in more partnerships like T-REX.

Financial difficulty during treatment for multiple myeloma (MM) or chronic lymphocytic leukemia (CLL) was associated with lower levels of education, incomes below $60,000, and multiple comorbidities.

In the second interview in a series, Takeda’s Lauren Powell, MPA, PhD, vice president, US Health Equity & Community Wellness, discussed how a partnership with Xavier University of Louisiana will unfold over several years.

Vall d'Hebron Institute of Oncology, a research group from Barcelona, Spain, has presented a method to detect FGFR2 fusion in plasma, which they say is “especially relevant” since the arrival of pemigatinib to treat patients with recurrent intrahepatic cholangiocarcinoma (iCCA).

In the second of 2 parts, Nathan H. Walcker, MBA, CEO of Florida Cancer Specialists & Research Institute (FCS), discusses what he’d like value-based care to look like going forward. CMS ended the Oncology Care Model (OCM) yesterday after 6 years and has invited practices to apply for a successor model, the Enhancing Oncology Model.

In the first of 2 parts, Nathan H. Walcker, MBA, CEO of Florida Cancer Specialists & Research Institute (FCS), discusses the future of value-based care for the practice as the Oncology Care Model comes to an end today. This week, CMS announced it will launch a successor model.

Today, CMS unveiled its plan for a successor to the Oncology Care Model (OCM), its ambitious foray into value-based care delivery that has been credited with changing the landscape for patients with cancer, even if it received mixed reviews on achieving savings in its early years.

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses the path of telemedicine reimbursement during the pandemic and possible ways it will change after the pandemic.

Why "tech-enabled" solutions make sense and how the Music City became the a health care hub.

Oncologist and health tech veteran Bobby Green, MD, who practiced for 17 years in Florida and was previously with Flatiron, is now Thyme Care’s president and chief medical officer. He has relocated to Nashville, Tennessee, to launch Thyme Care.

The Institute of Value-Based Medicine® (IVBM), hosted by Tennessee Oncology, brought health care leaders together on April 21 in Nashville, Tennessee, to discuss oncology care delivery—and to see colleagues in person, some for the first time since 2020.

Miruna Sasu, PhD, MBA, became president and CEO of COTA Healthcare in March 2022, not quite a year after joining the company as its chief strategy officer. As the importance of RWD grows, Sasu is ready to take its use in precision oncology to new levels. She spoke with Evidence-Based Oncology™ (EBO) about her new role.

Nathan H. Walcker, MBA, CEO of Florida Cancer Specialists & Research Institute (FCS) since August 2020, discusses the future of value-based care for the practice as the Oncology Care Model comes to an end.

Four experts from The US Oncology Network partnered with The American Journal of Managed Care® to present a webinar, “Beyond the OCM: How Are Commercial Payers & Employers Delivering Value-Based Cancer Care?”

The study, published in Current Medical Research and Opinion, finds that females were 22% more likely than males to have long COVID, which was defined as having symptoms that lasted more than 4 weeks after onset.

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses how enhancements to telemedicine precipitated by the COVID-19 pandemic have made lasting and meaningful changes to oncology care, including that these care improvements will persist post pandemic.

Anita Kumar, MD, medical oncologist with Memorial Sloan Kettering Cancer Center, led a session at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), on New Directions in Mantle Cell Lymphoma.

Hope S. Rugo, MD, FASCO, is professor of medicine and the director of the Breast Oncology and Clinical Trials Education program at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. She discusses her experience with palbociclib and letrozole in advanced breast cancer.

In a panel discussion, “Banner|Aetna: Collaboration as a Business Imperative,” part of the Matters in Managed Care webinar series, panelists discussed how payers and providers can work as partners to deliver care with aligned financial interests.

As part of its inquiry, the Federal Trade Commission (FTC) will demand that the 6 largest pharmacy benefit managers (PBMs) submit records and answer questions regarding their business practices.

The results involve a pair of DNA medicines combined with cemiplimab, which is approved as Libtayo to treat other solid tumors. In this study, the regimen is designed to prime a T-cell response before a patient receives radiation.

Kim A. Reiss, MD, assistant program director of the Hematology/Oncology Fellowship Program and assistant professor of medicine at the Hospital of the University of Pennsylvania, discusses pancreatic cancer research she presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Joel W. Neal, MD, PhD, associate professor, Division of Oncology, Stanford Cancer Institute, is lead investigator on the COSMIC-021 trial, which is investigating cabozantinib plus atezolizumab vs cabozantinib alone in patients with advanced non–small cell lung cancer (NSCLC) as a possible second-line treatment beyond chemotherapy.

Results presented at the American Society of Clinical Oncology Annual Meeting showed a 21.4-month advantage for autologous stem cell transplant (ASCT) over a common triplet therapy in progression-free survival (PFS) but no advantage in overall survival (OS).

Practice-changing data from the DESTINY-Breast04 study, presented during the 2022 Annual Meeting of the American Society of Clinical Oncology in Chicago, show that trastuzumab deruxtecan reduced the risk of disease progression or death by 50% compared with chemotherapy for human epidermal growth factor receptor-2 (HER2)–low patients with both hormone receptor (HR)–positive and HR-negative disease.

Thanos Zomas, MD, global medical lead, Lymphoma and Leukemia, and global medical lead, Adcetris Program, at Takeda Oncology discusses updated results from the ECHELON-1 study.

David R. Penberthy, MD, MBA, is medical director, Radiation Oncology, Bon Secours-Southside Medical Center in Petersburg, Virginia, and president of the Association of Community Cancer Centers for the 2022-2023 term.

TROPiCS-02, a phase 3 study, was presented during a session on breast cancer at the 2022 Annual Meeting of the American Society of Clinical Oncology.